513 related articles for article (PubMed ID: 22271481)
21. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer.
Pötter R; Gnant M; Kwasny W; Tausch C; Handl-Zeller L; Pakisch B; Taucher S; Hammer J; Luschin-Ebengreuth G; Schmid M; Sedlmayer F; Stierer M; Reiner G; Kapp K; Hofbauer F; Rottenfusser A; Pöstlberger S; Haider K; Draxler W; Jakesz R;
Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):334-40. PubMed ID: 17363187
[TBL] [Abstract][Full Text] [Related]
22. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
23. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Monnier AM
Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
[TBL] [Abstract][Full Text] [Related]
24. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
[TBL] [Abstract][Full Text] [Related]
25. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.
Ingle JN; Suman VJ; Mailliard JA; Kugler JW; Krook JE; Michalak JC; Pisansky TM; Wold LE; Donohue JH; Goetz MP; Perez EA
Breast Cancer Res Treat; 2006 Jul; 98(2):217-22. PubMed ID: 16538529
[TBL] [Abstract][Full Text] [Related]
26. Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy.
Akashi-Tanaka S; Omatsu M; Shimizu C; Ando M; Terada K; Shien T; Kinoshita T; Fujiwara Y; Seki K; Hasegawa T; Fukutomi T
Breast; 2007 Oct; 16(5):482-8. PubMed ID: 17418576
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
28. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
[TBL] [Abstract][Full Text] [Related]
29. Anastrozole: new indication. Adjuvant treatment of non metastatic breast cancer: useful for some patients.
Prescrire Int; 2005 Apr; 14(76):43-4. PubMed ID: 15875334
[TBL] [Abstract][Full Text] [Related]
30. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R
Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902
[TBL] [Abstract][Full Text] [Related]
31. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
[TBL] [Abstract][Full Text] [Related]
32. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
33. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen Anastrozole trial.
Boccardo F; Guglielmini P; Bordonaro R; Fini A; Massidda B; Porpiglia M; Roagna R; Serra P; Orzalesi L; Ucci G; Rubagotti A
Eur J Cancer; 2013 May; 49(7):1546-54. PubMed ID: 23415888
[TBL] [Abstract][Full Text] [Related]
34. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
35. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
[TBL] [Abstract][Full Text] [Related]
36. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
37. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
Goss PE; Ingle JN; Pater JL; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Tu D
J Clin Oncol; 2008 Apr; 26(12):1948-55. PubMed ID: 18332475
[TBL] [Abstract][Full Text] [Related]
38. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
Buzdar AU; Cuzick J
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122
[TBL] [Abstract][Full Text] [Related]
39. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
Muss HB; Tu D; Ingle JN; Martino S; Robert NJ; Pater JL; Whelan TJ; Palmer MJ; Piccart MJ; Shepherd LE; Pritchard KI; He Z; Goss PE
J Clin Oncol; 2008 Apr; 26(12):1956-64. PubMed ID: 18332474
[TBL] [Abstract][Full Text] [Related]
40. Overcoming recurrence risk: extended adjuvant endocrine therapy.
Cianfrocca M
Clin Breast Cancer; 2008 Dec; 8(6):493-500. PubMed ID: 19073503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
